19 Nov 2026, 10:51
Company Administration—
Announcement history available from 1 August 2025
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 19 Nov 2026, 10:51 | OSL to Present at Bell Potter Conference (Update to Time) | Company Administration | — | 12008 | |
| 18 Nov 2026, 12:00 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 18 Nov 2026, 10:13 | AGM Chairman's Address and CEO & MD Presentation | Presentations | — | 03026, 15002 | |
| 16 Nov 2026, 15:52 | OncoSil to Present at Bell Potter Healthcare Conference 2026 | Company Administration | — | 12008 | |
| 2 Nov 2026, 08:36 | Regulatory Application Filed for Australian Manufacturing | Company Update | — | 11001 | |
| 30 Oct 2026, 09:17 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 27 Oct 2026, 14:59 | Annual Report (Typeset) | Financial Results | — | 03001, 03002, 03011, 03012, 03013, 03020 | |
| 27 Oct 2026, 08:57 | Peer-Reviewed Study Reports 100% Disease Control | Company Update | — | 11001 | |
| 26 Oct 2026, 15:27 | Change of Director's Interest Notice | Director Interests | — | 02009 | |
| 26 Oct 2026, 15:24 | Notification of cessation of securities - OSL | Securities Administration | — | 06027 | |
| 21 Oct 2026, 09:10 | Updated OSPREY Overall Survival Data Presented at EAMN | Company Update | — | 11001 | |
| 19 Oct 2026, 10:01 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 15 Oct 2026, 15:34 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 13 Oct 2026, 09:59 | PALACROS Officially Launched in Amsterdam | Company Update | — | 11001 | |
| 30 Sept 2026, 09:27 | OncoSil Clinical Data to be Presented at EANM 2026 | Company Update | — | 11001 | |
| 28 Sept 2026, 13:26 | Notice of AGM date | Meetings & Governance | — | 08006 | |
| 15 Sept 2026, 09:04 | Notice under ASX Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 14 Sept 2026, 16:52 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 14 Sept 2026, 08:39 | Change in substantial shareholding from AEF | Substantial Holders | — | 02002 | |
| 10 Sept 2026, 11:21 | Notice Under Section 708A | Securities Administration | — | 06018 | |
| 10 Sept 2026, 11:20 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 10 Sept 2026, 11:16 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 9 Sept 2026, 08:43 | Australian Manufacturing Facility Achieves ISO 13485 | Company Update | MS | 11001 | |
| 8 Sept 2026, 09:40 | 100th Patient Treated with OncoSil device in Spain | Company Update | — | 11001 | |
| 7 Sept 2026, 17:12 | Proposed issue of securities - OSL | Securities Administration | — | 06013 | |
| 7 Sept 2026, 17:11 | OSL Secures $5.6 million from Major Institutional Investors | Capital Raising | MS | 06003 | |
| 2 Sept 2026, 11:33 | OncoSil submits US Reimbursement Application (Updated) | Company Update | — | 11001 | |
| 2 Sept 2026, 10:27 | OncoSil submits US Reimbursement Application | Company Update | — | 11001 | |
| 28 Aug 2026, 16:03 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 28 Aug 2026, 15:58 | Appendix 4E and Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 21 Aug 2026, 16:52 | Change in substantial holding | Substantial Holders | — | 02002 | |
| 20 Aug 2026, 09:22 | Change in substantial shareholding from AEF | Substantial Holders | — | 02002 | |
| 17 Aug 2026, 16:46 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 17 Aug 2026, 15:09 | Investor Webinar Presentation | Presentations | — | 03026 | |
| 17 Aug 2026, 08:35 | OncoSil Receives FDA Approval for Distal Cholangiocarcinoma | Company Update | MS | 11001, 14014 | |
| 30 July 2026, 08:42 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 24 July 2026, 08:40 | New Independent Study Confirms OncoSil Dose Flexibility | Company Update | — | 11001 | |
| 23 July 2026, 15:25 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 20 July 2026, 08:31 | OncoSil Medical Receives Saudi Arabia FDA Approval | Company Update | — | 11001 | |
| 17 July 2026, 15:31 | Application for quotation of securities - OSL | Securities Administration | — | 06020 | |
| 15 July 2026, 08:57 | Investor Presentation | Presentations | — | 03026 | |
| 14 July 2026, 08:54 | OSPREY Registry Abstract Accepted for EANM 2026 Congress | Company Update | — | 11001 | |
| 13 July 2026, 08:39 | OncoSil Medical Completes Manufacturing Validation | Company Update | MS | 11001 | |
| 6 July 2026, 08:49 | TRIPP-FFX Results Presented at ESMO GI 2026 | Company Update | — | 11001 | |
| 3 July 2026, 08:27 | OncoSil Medical Files for FDA Approval | Company Update | MS | 11001 | |
| 2 July 2026, 08:46 | OncoSil Selected for Major European Pancreatic Cancer Study | Company Update | MS | 11001 | |
| 30 June 2026, 08:47 | TRIPP-FFX Abstract Published on ESMO GI 2026 Website | Company Administration | — | 12008 | |
| 29 June 2026, 15:54 | Notice under ASX Listing Rule 3.10A | Securities Administration | — | 06009 | |
| 12 June 2026, 09:04 | Publication verifies OncoSil strong localisation in pancreas | Company Update | — | 11001 | |
| 12 June 2026, 08:30 | OncoSil Medical Launches Investor Hub | Presentations | — | 14014 |